BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25563558)

  • 1. A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.
    Yang J; Shi Y; He X; Dong M; Zhang C; Liu P; Zhou S; Qin Y; Gui L; Yang S; Sun Y
    Leuk Lymphoma; 2015 Jul; 56(7):2218-21. PubMed ID: 25563558
    [No Abstract]   [Full Text] [Related]  

  • 2. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
    Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
    [No Abstract]   [Full Text] [Related]  

  • 3. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
    Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
    Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
    Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
    Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
    Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
    Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
    Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of brainstem involvement in NK/T cell lymphoma.
    So JC; Chan KH; Pang AW; Chan JK; Kwong YL
    Ann Hematol; 2014 Aug; 93(8):1433-4. PubMed ID: 24292537
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
    Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
    Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
    Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
    Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
    Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
    Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type.
    Zheng Y; Yang C; Liang T; Yang D; Liu Z
    Hematol Oncol; 2020 Feb; 38(1):103-105. PubMed ID: 31102421
    [No Abstract]   [Full Text] [Related]  

  • 12. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
    Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
    Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant.
    Inoue D; Nagai Y; Takiuchi Y; Nagano S; Arima H; Kimura T; Shimoji S; Mori M; Togami K; Tabata S; Yanagita S; Matsushita A; Nagai K; Maruoka H; Imai Y; Suzuki R; Takahashi T
    Leuk Lymphoma; 2010 Apr; 51(4):720-3. PubMed ID: 20233057
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
    Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M
    Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extranodal NK/T cell lymphoma, nasal type, presenting with meningeal infiltration in a Caucasian female.
    Hildyard C; Sheikh S; Eyre T; Collins G
    Br J Haematol; 2013 Dec; 163(5):550. PubMed ID: 24033120
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
    Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
    Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
    Farid M; Yau YW; Tay K; Quek R; Tao M; Koo GC; Loong S; Lim ST
    Acta Oncol; 2011 May; 50(4):589-90. PubMed ID: 21226543
    [No Abstract]   [Full Text] [Related]  

  • 19. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone.
    Kim BS; Kim DW; Im SA; Kim CW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
    Ann Oncol; 2009 Jan; 20(1):121-8. PubMed ID: 18684695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
    Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
    Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.